Abbott LaboratoriesABTNYSE
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank51
5Y CAGR-31.7%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
-31.7%/yr
Long-term compound
Percentile
P51
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 14.62% |
| Q3 2025 | 48.28% |
| Q2 2025 | 65.59% |
| Q1 2025 | -56.56% |
| Q4 2024 | -0.05% |
| Q3 2024 | 50.60% |
| Q2 2024 | 127.59% |
| Q1 2024 | -72.54% |
| Q4 2023 | 73.35% |
| Q3 2023 | 89.22% |
| Q2 2023 | -8.78% |
| Q1 2023 | -55.54% |
| Q4 2022 | -25.81% |
| Q3 2022 | 13.88% |
| Q2 2022 | 16.46% |
| Q1 2022 | -28.90% |
| Q4 2021 | 9.51% |
| Q3 2021 | 30.61% |
| Q2 2021 | -23.44% |
| Q1 2021 | -28.18% |
| Q4 2020 | 98.66% |
| Q3 2020 | 130.88% |
| Q2 2020 | 91.55% |
| Q1 2020 | -82.09% |
| Q4 2019 | 28.12% |
| Q3 2019 | 161.32% |
| Q2 2019 | 57.03% |
| Q1 2019 | -70.96% |
| Q4 2018 | -29.03% |
| Q3 2018 | 93.34% |
| Q2 2018 | 13.57% |
| Q1 2018 | -35.68% |
| Q4 2017 | -25.66% |
| Q3 2017 | 58.94% |
| Q2 2017 | 262.91% |
| Q1 2017 | -64.51% |
| Q4 2016 | -5.97% |
| Q3 2016 | 36.71% |
| Q2 2016 | 297.02% |
| Q1 2016 | -157.93% |